US Biotechnology *VIDEO* Tenvie Therapeutics at UBS Private Biotech Summit: First NLRP3 biomarker data in Q4 to support CNS-penetrant obesity/CV thesis

Research evidence excerpt

US Biotechnology *VIDEO* Tenvie Therapeutics at UBS Private Biotech Summit: First NLRP3 biomarker data in Q4 to support CNS-penetrant obesity/CV thesis

CV benefits while addressing the root neuroinflammatory drivers of obesity. Preclinical

data are indicative of synergistic weight loss effects of adding NLRP3 on top of

semaglutide at therapeutically relevant doses. The added benefit in combination would

be the ability to achieve similar weight loss at lower levels of GLP1 which could help

mitigate AEs seen with the incretin class.

With their Phase I data Tenvie will aim to (1) recapitulate the CV biomarker data

shared by VTYX and others and (2) share data on additional, unique biomarkers

to support the cardiometabolic thesis. Tenvie plans to move TNV262 quickly into

Phase II studies in CVD and obesity which could initiate by YE and read out in Q4/27

pending first Phase I data by Q4. Note co also has second CNS-penetrant NLRP3 inhibitor

set to enter the clinic in August (pot'l here to assess this candidate in neurologic diseases

or other indications vs. TNV262) as well as a preclinical candidate that is peripherally

restricted.

Tenvie's second asset is a peripherally-restricted SARM1 inhibitor for the

treatment of peripheral neuropathies in a Phase I HV trial. Co will have first Phase

I safety and PK data in H2/26 and is looking at PK/PD and biomarkers related to pathway

modulation and neuroprotection. Co also has a CNS-penetrant SARM1 inhibitor

planned to enter the clinic next year to address CNS indications relevant to SARM1.

SARM1 is thought to be a root cause/master executer of axonal degeneration and

subsequently neuronal death. By inhibiting SARM1, preclinical data demonstrate

protection against nerve degeneration in peripheral neuropathies. Potential indications